These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

251 related items for PubMed ID: 19898693

  • 1. Cardiac risk assessment before the use of stimulant medications in children and youth: A joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry.
    Warren AE, Hamilton RM, Bélanger SA, Gray C, Gow RM, Sanatani S, Côté JM, Lougheed J, LeBlanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.
    Can J Cardiol; 2009 Nov; 25(11):625-30. PubMed ID: 19898693
    [Abstract] [Full Text] [Related]

  • 2. Cardiac risk assessment before the use of stimulant medications in children and youth.
    Bélanger SA, Warren AE, Hamilton RM, Gray C, Gow RM, Sanatani S, Côté JM, Frcpc JL, Leblanc J, Martin S, Miles B, Mitchell C, Gorman DA, Weiss M, Schachar R.
    Paediatr Child Health; 2009 Nov; 14(9):579-92. PubMed ID: 21037835
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Cardiovascular risks and management during Attention Deficit Hyperactivity Disorder treatment with methylphenidate].
    Bange F, Le Heuzey MF, Acquaviva E, Delorme R, Mouren MC.
    Arch Pediatr; 2014 Jan; 21(1):108-12. PubMed ID: 24309201
    [Abstract] [Full Text] [Related]

  • 5. Attention deficit hyperactivity disorder medications in children with heart disease.
    Berger S.
    Curr Opin Pediatr; 2016 Oct; 28(5):607-12. PubMed ID: 27261563
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder.
    Perrin JM, Friedman RA, Knilans TK, Black Box Working Group, Section on Cardiology and Cardiac Surgery.
    Pediatrics; 2008 Aug; 122(2):451-3. PubMed ID: 18676566
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Cardiovascular risk of stimulant treatment in pediatric attention-deficit/hyperactivity disorder: update and clinical recommendations.
    Hammerness PG, Perrin JM, Shelley-Abrahamson R, Wilens TE.
    J Am Acad Child Adolesc Psychiatry; 2011 Oct; 50(10):978-90. PubMed ID: 21961773
    [Abstract] [Full Text] [Related]

  • 11. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes.
    Faraone SV, Glatt SJ.
    J Clin Psychiatry; 2010 Jun; 71(6):754-63. PubMed ID: 20051220
    [Abstract] [Full Text] [Related]

  • 12. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM, Earls MF.
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [Abstract] [Full Text] [Related]

  • 13. Survey of United States child and adolescent psychiatrists' cardiac screening practices prior to starting patients on stimulants.
    Leslie LK, Rodday AM, Saunders TS, Cohen JT, Wong JB, Sheldrick RC, Parsons SK.
    J Child Adolesc Psychopharmacol; 2012 Oct; 22(5):375-84. PubMed ID: 23083024
    [Abstract] [Full Text] [Related]

  • 14. Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder.
    Leslie LK, Alexander ME, Trikalinos TA, Cohen JT, Parsons SK, Newburger JW.
    Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):134-7. PubMed ID: 20031801
    [No Abstract] [Full Text] [Related]

  • 15. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder.
    Denchev P, Kaltman JR, Schoenbaum M, Vitiello B.
    Circulation; 2010 Mar 23; 121(11):1329-37. PubMed ID: 20212277
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder.
    Silva RR, Skimming JW, Muniz R.
    Clin Pediatr (Phila); 2010 Sep 23; 49(9):840-51. PubMed ID: 20693523
    [Abstract] [Full Text] [Related]

  • 17. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association.
    Goldman LS, Genel M, Bezman RJ, Slanetz PJ.
    JAMA; 1998 Apr 08; 279(14):1100-7. PubMed ID: 9546570
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Stimulants and sudden death: what is a physician to do?
    Wilens TE, Prince JB, Spencer TJ, Biederman J.
    Pediatrics; 2006 Sep 08; 118(3):1215-9. PubMed ID: 16951018
    [Abstract] [Full Text] [Related]

  • 20. Stimulants for kids with ADHD--how to proceed safely.
    Ken Mehta S, Jacobs I.
    J Fam Pract; 2014 Feb 08; 63(2):E1-5. PubMed ID: 24527478
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.